Protection cardio-rénale par les inhibiteurs des SGLT2 (gliflozines) : d’EMPA-REG OUTCOME à CANVAS
Explore this paper's citation graph
Summary
Ces résultats plaident pour un effet de classe des inhibiteurs des cotransporteurs sodium-glucose de type 2 (SGLT2).
- Type
- article
- Published
- 2017-01-01
- Cited by
- 4
- References
- 31
- OpenAlex
- https://openalex.org/W2761748726
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:79838502
Keywords
EMPA, Medicine, Chemistry
References
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
- Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
- SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
- Actualisation 2015 du traitement de l'hyperglycemie dans le diabete de type 2.
- Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis.
- Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
- SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
- SGLT2 Inhibitors: Benefit/Risk Balance
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
- Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
- Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
- Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials
Cited by
- Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2
- Perspectives dans le traitement pharmacologique du diabète de type 2 pour les 10 prochaines années
- Inhibiteur des SGLT2 ou analogue du GLP-1 chez un patient diabétique avec maladie cardiovasculaire ?
- Études cardiovasculaires chez le patient diabétique de type 2 à risque : conclusions et impact des essais publiés en 2017-2018
Related papers
No related papers recorded.